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Background. Dengue virus serotypes 1–4 (DENV-1–4) are the most common vector-borne viral pathogens of humans and the 
etiological agents of dengue fever and dengue hemorrhagic syndrome. A live-attenuated tetravalent dengue vaccine (TDV) devel-
oped by Takeda Vaccines has recently progressed to phase 3 safety and efficacy evaluation.
Methods. We analyzed the qualitative features of the neutralizing antibody (nAb) response induced in naive and DENV-immune 
individuals after TDV administration. Using DENV-specific human monoclonal antibodies (mAbs) and recombinant DENV dis-
playing different serotype-specific Ab epitopes, we mapped the specificity of TDV-induced nAbs against DENV-1–3.
Results. Nearly all subjects had high levels of DENV-2–specific nAbs directed to epitopes centered on domain III of the enve-
lope protein. In some individuals, the vaccine induced nAbs that tracked with a DENV-1–specific neutralizing epitope centered on 
domain I of the envelope protein. The vaccine induced binding Abs directed to a DENV-3 type-specific neutralizing epitope, but 
findings of mapping of DENV-3 type-specific nAbs were inconclusive.
Conclusion. Here we provide qualitative measures of the magnitude and epitope specificity of the nAb responses to TDV. This 
information will be useful for understanding the performance of TDV in clinical trials and for identifying correlates of protective 
immunity.
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Dengue viruses (DENVs) are positive-sense RNA viruses trans-
mitted to humans through mosquito vectors. DENV consists of 
4 serotypes (DENV-1–4) that cocirculate in tropical and sub-
tropical regions, where an estimated 390 million individuals 
are infected per year [1]. While most infections are clinically 
inapparent or mild, about 25% of infections cause acute febrile 
illness and occasionally progress to severe dengue hemorrhagic 
syndrome [2, 3].
Neutralizing antibodies (nAbs) are considered a necessary 
component of protective immunity to DENVs [4, 5]. Primary 
infection with a DENV serotype induces a nAb response that 
provides long-term protection against the infecting serotype 
but limited and transient protection against other serotypes. 
Secondary infections with a different serotype may stimulate 
an immune-enhanced severe disease [5, 6]. Given the risk of 
immune-enhanced disease, leading vaccine candidates are 
tetravalent to simultaneously induce a balanced protective 
response to all 4 serotypes [7–9].
The DENV envelope (E) protein binds to cellular receptors, 
mediates viral entry and fusion, and is the main target of nAbs 
and protective Abs [10–12]. The ectodomain of E is composed 
of 3 domains: I, II, and III (EDI, EDII, and EDIII). Each DENV 
virion has 180 monomers of E, organized into 90 dimers that 
cover the entire virus surface. Type-specific nAbs have been iso-
lated from individuals infected with different DENV serotypes 
[13–16]. Many human DENV nAbs bind to complex quater-
nary E protein epitopes displayed on intact virions but not on 
recombinant E protein monomers [17]. Our recent studies have 
demonstrated that DENV type–specific epitopes defined by 
human monoclonal Ab (mAbs) are also targeted by polyclonal 
serum nAbs in people exposed to DENV infections [13, 14].
A live attenuated tetravalent DENV vaccine (TDV) devel-
oped by Sanofi Pasteur (Dengvaxia) has been evaluated in 2 
large efficacy studies and licensed for use in several countries 
[18]. In Dengvaxia clinical trials, some people with DENV 
nAbs experienced breakthrough infections demonstrating 
that mere presence of nAb was insufficient for protection [18]. 
Recently, Sanofi announced that Dengvaxia should only be used 
in people with preexisting immunity to DENV because naive 
individuals who receive the vaccine may be at increased risk of 
developing severe disease. These data suggest the need for new 
diagnostic approaches to determine the quality and molecular 
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specificity of nAbs to identify correlates and mechanisms of 
protective immunity.
Takeda’s vaccine candidate consists of an attenuated DENV-2 
virus (TDV2) and 3 recombinant chimeric viruses for DENV-1, 
-3, and -4, generated by reverse genetic replacement of the genes
encoding structural surface proteins prM and E of TDV2 with genes 
from representative members of the other 3 serotypes [7, 19–22].
TDV is immunogenic and efficacious in animal models, and, on
the basis of immunogenicity and safety results of phase 1 and 2 tri-
als in humans, pivotal phase 3 trials were initiated in late 2016 in
dengue-endemic regions [21, 23–26]. In this study, we used DENV
serotype–specific human mAbs and recombinant DENVs that dis-
play Ab epitopes of interest [14, 27] to map the specificity of the nAb 
responses elicited by an early formulation of Takeda’s TDV [21].
MATERIALS AND METHODS
Ethics Statement
This study used deidentified human samples under University 
of North Carolina Institutional Review Board exemption 
approval 15-0015. Samples were collected by Takeda Vaccines 
in 2 completed clinical trials (studies 104 and 203) in accord-
ance with the Edinburgh revision of the Declaration of Helsinki, 
International Conference on Harmonization and Good Clinical 
Practice guidelines, and applicable national and local regula-
tions and requirements. The protocols were approved by the 
local internal review boards and are registered on ClinicalTrials.
gov (NCT01542632 and NCT01511250).
Source of Serum Samples
Study 104 was a double-blinded, randomized phase 1b trial 
conducted in the United States among participants aged 
18–45 years [24]. For study 104, all subjects were DENV sero-
negative prior to vaccination. To facilitate epitope mapping, 
only subjects with a 50% nAb titer (NT50) of ≥60 to particu-
lar DENV serotypes were selected for the current study. Study 
203 was a double-blinded, randomized, placebo-controlled, 
phase 2 trial conducted in Puerto Rico, Colombia, Singapore, 
and Thailand among participants aged 1.5–45  years [25]. As 
reported previously [25], among participants who were DENV 
seronegative prior to vaccination, >94% developed nAbs to 
DENV-1, DENV-2, or DENV-3, and 58.6% developed nAbs 
to DENV-4 on day 28 after the first dose. The frequency with 
nAbs to DENV-4 increased to 87.7% following the second dose. 
Among participants who were seropositive to at least 1 DENV 
serotype at baseline, the frequency of nAbs to DENV-1–4 were 
91.3%–99.1% after 1 dose and 96.5%–100% after 2 doses. Study 
203 samples were selected for the current study without pre-
screening for particular nAb profiles.
Cells and Viruses
Viruses were propagated in C6/36 Aedes albopictus cells, which 
were grown in minimal essential medium (Gibco, Grand Island, 
NY) at 32°C. Vero-81 cells were grown in Dulbecco’s modified 
Eagle’s medium (Gibco), while U937+DC-SIGN cells were 
maintained in Roswell Park Memorial Institute 1640 medium 
(Gibco) at 37°C. Media were supplemented with 5% fetal bovine 
serum (HyClone, Logan, UT), 0.1 mM nonessential amino acids 
(Gibco), 100 U/mL penicillin (Gibco), and 100 mg/mL strepto-
mycin (Gibco). U937+DC-SIGN medium was supplemented 
with 2  mM GlutaMAX (Gibco), 10mM HEPES (Cellgro, 
Manassas, VA), and 2-mercaptoethanol (Sigma, St. Louis, MO). 
Cells were incubated in the presence of 5% CO2.
Recombinant chimeric viruses were constructed using a quadri-
partite complementary DNA clone, the same strategy used to cre-
ate wild-type DENV [14, 27, 28]. DENV-1 (West Pac ́ 74), DENV-2 
(S-16803), DENV-3 (Sri Lanka ʹ89), and DENV-4 (Sri Lanka ʹ92) 
strains were used in the present study. Epitope-transplanted recom-
binant DENVs were as follows: DENV-3 with the 1F4 epitope from 
DENV-1 (DV3/1), DENV-4 with the E domain III from DENV-2 
(DV4/2), DENV 4 with the 5J7 epitope from DENV-3 (DV4/3). 
Full-length cDNA was transcribed into genome-length RNAs 
using T7 polymerase and recombinant viruses isolated in C6/36 
cells as previously described [14, 27–29]. Virus was then passaged 
twice on C6/36 cells, centrifuged to remove cellular debris, and the 
3rd passage was stored at −80°C as a working stock. DENV strains 
used in blockade of binding assays include DENV-1 West Pac ʹ74, 
DENV-2 S-16803, DENV-3 CH-53489, and DENV-4 TVP-376.
In Vitro Neutralization
Human sera or mAbs were serially diluted 3-fold in medium 
containing 2% fetal bovine serum and mixed with sufficient 
virus to infect 15% of the U937+DC-SIGN cells. Virus and Ab 
mixtures were incubated for 45 minutes in 96-well plates at 
37°C and mixed with 5 × 104 cells for 2 hours at 37°C. Unbound 
virus was washed with infection media, the volume of medium 
in each well was increased to 200 μL, and the cells were incu-
bated again at 37°C. After 24 hours, the cells were washed with 
fetal bovine serum, fixed in paraformaldehyde, permeabilized 
with saponin, blocked with normal mouse serum, and stained 
with AlexaFluor 488–conjugated (Molecular Probes, Eugene, 
OR) 2H2 Ab. Unbound Ab was removed, and the cells were 
resuspended in Hank’s buffered salt solution (Gibco, Grand 
Island, NY) supplemented with 2% fetal bovine serum. Assays 
were performed twice and in duplicate. Samples were read on a 
Guava easyCyte 5HT flow cytometer (Millipore) [30].
Blockade of Binding Assay
Enzyme immunoassay plates were coated with 4G2 mouse Ab 
to capture DENV-1 or DENV-3. After 1 hour, polyclonal sera 
were added in 2-fold dilutions and incubated for 1 hour at 37°C. 
Labeled human mAb (1F4 for DENV-1 and 5J7 for DENV-3) 
was used to detect quaternary epitopes not blocked by the poly-
clonal sera. Plates were washed, the color was developed, and 
the amount of mAb binding that was blocked by polyclonal 
sera was compared to mAb binding in the absence of sera, with 
results reported as the percentage of binding blockaded.
Antigenic Cartography
Antigenic cartography was performed using the NT50 values 
generated from the neutralization assays. Data were normalized 
as described by Cai et al [31]. Euclidean distances between sera 
were calculated, and metric multidimensional scaling was used 
to render data in 3 dimensions [32]. Calculations and images 
were generated in RStudio, version 0.99.467 (RStudio, Boston, 
MA).
Statistical Analysis
NT50 values were calculated using the sigmoidal dose response 
(variable slope) equation in Prism 7 (GraphPad, La Jolla, CA). 
Log-transformed data from the NT50 values were used to cal-
culate geometric mean titers (GMTs) and 95% confidence 
intervals (CIs). Variation between groups was measured by the 
Wilcoxon signed rank test for repeated measurements without 
normal distribution. P values of <.05 were considered statisti-
cally significant.
RESULTS
Baseline Characterization of Serum Samples From TDV Recipients
Volunteers from dengue-endemic regions who were enrolled in 
study 203 received 1 dose of TDV on day 0 and a second dose on 
day 90 (Figure 1). To map the epitopes targeted by vaccine-in-
duced nAbs, we selected serum samples from 24 study subjects, 
collected on day 0 (before vaccination) and day 120 (1 month 
after the second dose). Of the 24 subjects, 11 had DENV-naive 
serum samples and 13 had DENV-preimmune serum samples 
prior to vaccination.
To evaluate epitope-specific responses following vaccination, 
we first measured levels of serum nAbs against the parental 4 
DENV infectious clone–derived recombinant viruses, using 
flow cytometry and U937 cells expressing DC-SIGN (a DENV 
attachment receptor; Figures 2 and 3). At day 0, serum from 
0 of 11 naive individuals had DENV nAbs (Figure  3A and 
Supplementary Table 1). At day 120, serum from 6 naive indi-
viduals neutralized DENV-1 West Pac ʹ74 (GMT, 86), serum 
from 11 neutralized DENV-2 S16803 (GMT, 1233), serum 
from 7 neutralized DENV-3 Sri Lanka ʹ89 (GMT, 74), and 
serum from 7 neutralized DENV-4 Sri Lanka ʹ92 (GMT, 58; 
Figure 3A). Of the 13 preimmune subjects, before vaccination 
serum from 11 neutralized DENV-1 (GMT, 150), serum from 
13 neutralized DENV-2 (GMT, 322), serum from 11 neutralized 
DENV-3 (GMT, 138), and serum from 7 neutralized DENV-4 
(GMT, 62). By day 120, all vaccinated preimmune subjects had 
boosted responses, with elevated neutralizing titers against 
DENV-1 (GMT, 1637), DENV-2 (GMT, 898), DENV-3 (GMT, 
571), and DENV-4 (GMT, 338; Figure 3B and Supplementary 
Table 1).
Mapping the Vaccine-Induced DENV-1 Epitope-Specific Response
A chimeric virus was used to determine whether DENV-1 nAbs 
induced by TDV targeted a type-specific EDI/EDII hinge region 
epitope defined by human mAb 1F4 (Figure 2). The DENV-1 
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Figure 1.  Study design. A, The live attenuated tetravalent dengue vaccine (TDV) vaccine is composed of an attenuated dengue virus serotype 2 (DENV-2) backbone with 
prM and E from DENV-1 for TDV-1, prM and E from DENV-3 for TDV-3, and prM and E from DENV-4 for TDV-4. B, Subjects were immunized with the tetravalent vaccine at 
days 0 and 90. Serum samples were collected on day 0 before vaccination and on day 120, 30 days after the second dose. C, Study sites were located in the United States 
(Study 104) and Thailand, Colombia, Puerto Rico, and Singapore (Study 203).
against rDENV-3/1 were significantly higher (GMT, 755) than 
the nAb titers against the parental DENV-3 (GMT, 178; P < .05; 
Figure 4A). Blockade of 1F4 binding assays also demonstrated 
a significant increase in mean blockade of 1F4 binding to 
DENV-1 at a serum dilution of 1:20 between day 0 (2%) and 
day 120 (33%; P <  .05; Figure  4B). In study 104 subjects (all 
of whom were naive prior to vaccination) [24], neutralization 
type-specific 1F4 epitope is sensitive to the angle of the EDI/II 
hinge and is present in DENV-1 virions but not recombinant E 
protein secreted from cells as a monomer [13]. From the TDV-
receiving naive cohort, 6 subjects with DENV-1 nAb titers >1:20 
at day 120 were tested for neutralization of DENV-1, DENV-3, 
and the DENV-3/1 chimera (Figure  4A). Among the 6 naive 
subjects with a postvaccination DENV-1 response, nAb titers 
against rDENV-3/1 were significantly higher (GMT, 755) than 
the nAb titers against the parental DENV-3 (GMT, 178; P < .05; 
Figure 4A). Blockade of 1F4 binding assays also demonstrated 
a significant increase in mean blockade of 1F4 binding to 
DENV-1 at a serum dilution of 1:20 between day 0 (2%) and 
day 120 (33%; P  <  .05; Figure  4B). In study 104 subjects (all 
of whom were naive prior to vaccination) [24], neutralization 
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Figure 3. Preimmunization and postimmunization neutralizing antibody (nAb) titers against wild-type dengue viruses (DENVs). Neutralization assays were performed and 
the geometric mean titer (GMT) calculated against DENV-1, DENV-2, DENV-3, and DENV-4 on day 0 and day 120 in subjects who were naive at day 0 (A) or preimmune at day 
0 (B). Bars represent the GMT and whiskers the 95% confidence interval. Dashed line indicates the limit of detection for the assay. Nonresponders were assigned a value of 
half of the limit of detection, for visualization. Within each graph, each individual is assigned the same color, to enable visualization of each person’s nAb titers to the different 
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Figure 2. Viruses used for characterization. Wild-type dengue virus (DENV) infectious clones of DENV-1 (West Pac ʹ74), DENV-2 (S-16803), DENV-3 (Sri Lanka ʹ89), and 
DENV-4 (Sri Lanka ʹ92) strains were used in the present study. The following epitope-transplanted recombinant DENVs were used for the U937+DC-SIGN flow-based neutral-
ization assay: DENV-3 with the 1F4 epitope from DENV-1 (DV3/1), DENV-4 with the E domain III from DENV-2 (DV4/2), and DENV-4 with the 5J7 epitope from DENV-3 (DV4/3). 
Natural isolates of the World Health Organization reference strains DENV-1 West Pac ʹ74 and DENV-3 CH-53489 were used for the blockade of binding assay.
findings for DENV-1 and DENV-3 was not statistically different 
(Supplementary Figure 1A), yet an increase in blockade of 1F4 
binding was observed between day 0 (0%) and day 120 (26.9%; 
P  <  .05; Supplementary Figure  1C). Preimmune individuals 
with DENV-1 nAb titers after vaccination (Figure 4C) did not 
have significantly different levels of nAb to rDENV-3/1 (GMT, 
1368)  and DENV-3 (GMT, 602). However, in the blockade 
of binding assay, blockade at day 120 (43%) was significantly 
greater than blockade at day 0 (22%; P < .05; Figure 4D). These 
results demonstrate that TDV can elicit type-specific DENV-1 
1F4-like nAbs in some individuals.
Mapping the Vaccine-Induced DENV-2 Response
We previously described a recombinant DENV-4/2 chimeric 
virus containing an E protein with EDI and II from DENV-4 
and EDIII from DENV-2 [14, 33]. This chimera displays a 
DENV-2 quaternary structure epitope centered on EDIII rec-
ognized by strongly neutralizing human mAb 2D22 [14]. After 
vaccination, all naive subjects had high DENV-2 nAbs titers 
(GMT, 1233; Figure 5A) and modest DENV-4 nAbs titers (GMT, 
58; Figure 5A). DENV-4/2 neutralization (GMT, 2058) was sig-
nificantly higher than observed for the parental DENV-4 strain 
(P < .05; Figure 5A). Study 104 subjects (all of whom were naive 
prior to vaccination) had higher titers of nAbs to DENV-4/2 
as compared to DENV-4, as well (Supplementary Figure  1B; 
P < .05). DENV-preimmune subjects who received TDV devel-
oped higher titers against rDENV-4/2 (GMT, 1993)  as com-
pared to DENV-4 (GMT, 338; P < .05; Figure 5B). These results 
demonstrate that, in both naive and DENV-preimmune sub-
jects, TDV induces robust DENV-2 nAbs that target type-spe-
cific epitopes centered on EDIII of DENV-2.
Mapping the Vaccine-Induced DENV-3 Response
We used a recombinant DENV-4/3 M14 chimeric virus to deter-
mine whether DENV-3 nAbs induced by TDV targeted a quater-
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Figure 4. Mapping the dengue virus serotype 1 (DENV-1) epitope-specific neutralizing antibody (nAb) response. Immune sera from naive subjects (A and B) and preimmune 
subjects (C and D) who received the vaccine and developed DENV-1 nAbs (50% nAb titer [NT50] >1:20) were selected for mapping DENV-1 responses. Neutralization assays 
were performed using a recombinant chimeric DENV-3/1 and the wild-type (WT) DENV-1 and DENV-3 parental strains of the chimera. Geometric mean NT50 values (GMTs) 
were calculated for the naive (A) and preimmune (C) groups after vaccination. Bars represent the GMT and whiskers the 95% confidence interval. Dashed line indicates the 
limit of detection for the assay. DENV-3 and DENV-3/1 nonresponders were assigned a value of half the limit of detection, for visualization. Prevaccination and postvacci-
nation immune sera from naive (B) and preimmune (D) subjects were also tested for ability to block the binding of monoclonal Ab 1F4 to DENV-1. Within each graph, each 
individual is assigned the same color, to enable visualization of each person’s nAb titers to the different viruses. *P < .05, by the Wilcoxon test, for comparison of the parental 
backbone DENV to the rDENV.
monomers, defined by human mAb 5J7 (Figure  2) [34]. We 
transplanted the 5J7 epitope core from DENV-3 into DENV-4; 
this recombinant chimeric virus was efficiently neutralized by 
mAb 5J7 [29]. The 7 naive subjects with DENV-3 nAb titers of 
>1:20 after vaccination were tested for neutralization of DENV-3,
DENV-4, and DENV-4/3 (Figure 6). In these individuals, the nAb
titers were not significantly different between DENV-4/3 (GMT,
243) and the parental DENV-4 (GMT, 81; P < .1841; Figure 6A).
From the naive group, immune sera collected after vaccination
blocked the binding of mAb 5J7 to DENV-3, demonstrating the
presence of serum Abs that bind at or near the epitope (Figure 6B).
However, no significant neutralization or blockade was observed
with Study 104 subjects (all naive prior to vaccination) after vac-
cination (Supplementary Figures 1B and 1D). After vaccination,
DENV-3 nAbs in the preimmune group did not significantly
track with the 5J7 epitope displayed on the DENV-4/3 chimera
(Figure 6C). However, the sera blocked binding of 5J7, suggesting
the presence of Abs that bind at or near the epitope (Figure 6D).
Antigenic Cartography
As an alternate strategy to detect the tracking of TDV-induced 
Ab with transplanted epitopes, we performed antigenic car-
tography of the wild-type and recombinant DENVs, using 
the neutralization data generated from TDV immune sera 
(Figure 7 and Supplementary Figure 2). In the antigenic map 
created by this analysis, the antigenic position of the DENV-
4/2 recombinant virus moved away from the parental back-
bone of DENV-4 toward that of DENV-2, indicating that TDV 
induces responses directed to the DENV-2 domain displayed 
on DENV-4 (Figure 7). Cartography findings indicate that TDV 
induces a robust type-specific response to DENV-2 and variable 
responses to DENV-1 and 3 epitopes.
DISCUSSION
We have evaluated the epitope specificity of DENV nAbs 
induced by TDV in naive and dengue-preimmune individuals. 
Epitope-specific measurements are important because people 
exposed to primary DENV infection develop a strong nAb 
response that targets serotype-specific epitopes that protect 
against homologous-serotype infection. It is unclear whether 
individuals who receive tetravalent dengue vaccines develop 
primary serotype-specific responses or broadly cross-reactive 
Ab responses that target each vaccine component. Also unclear 
is the role of these responses in durable protection against the 4 
serotypes. A recent study demonstrated that dengue-naive indi-
viduals who received a tetravalent chimeric yellow fever–den-
gue (CYD) vaccine mainly had type-specific nAbs to DENV-4 
and cross-reactive nAbs to the other serotypes [9]. The DENV-2 
response, in particular, was dominated by nAbs directed to 
cross-reactive epitopes, and overall CYD vaccine efficacy was 
lowest against this serotype in clinical trials [9].
Natural DENV-2 infection elicits human mAb 2D22–like 
type-specific nAbs that bind to a quaternary epitope spanning 
the EDIII and EDII of a single E protein homodimer [14, 33]. 
The recombinant chimeric DENV-4/2 displays the 2D22 quater-
nary epitope, allowing us to track linear EDIII and quaternary 
“2D22-like” responses in human immune sera after infection 
and vaccination [14, 33]. The Takeda TDV induced robust 
DENV-2–specific nAbs that tracked with EDIII on DENV-4/2. 
These studies could not differentiate between nAbs directed 
to simple epitopes contained with EDIII and more-complex 
“2D22-like” responses that require both EDIII and residues on 
adjacent E molecules. Blockade of binding assays with TDV 
immune sera and human mAb 2D22 could not be performed, 







































Figure 5. Mapping the dengue virus serotype 2 (DENV-2) epitope-specific neutralizing antibody (nAb) response. Immune sera from naive (A) and preimmune (B) subjects 
who received the vaccine and developed DENV-2 nAbs (50% nAb titer [NT50] >1:20) were selected for mapping DENV-2 responses. Neutralization assays were performed 
using a recombinant chimeric DENV-4/2 and the wild-type DENV-2 and DENV-4 parental strains of the chimera, and the geometric mean NT50 values (GMTs) were calculated 
for the naive (A) and preimmune (B) groups after vaccination. Bars represent the GMT and whiskers the 95% confidence interval. Dashed line indicates the limit of detection 
for the assay. Nonresponders were assigned a value of half the limit of detection, for visualization. Within each graph, each individual is assigned the same color, to enable 
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Figure 6. Mapping the dengue virus serotype 3 (DENV-3) epitope-specific neutralizing antibody (nAb) response. Immune sera from naive (A and B) and preimmune (C and D) 
subjects who received the vaccine and developed DENV-3 nAb (50% nAb titer [NT50]  >1:20) were selected for mapping DENV-3 responses. Neutralization assays were per-
formed using a recombinant chimeric DENV-4/3 and the wild-type (WT) DENV-3 and DENV-4 parental strains of the chimera, and the geometric mean NT50 values (GMTs) were 
calculated for the naive (A) and preimmune (C) groups after vaccination. Bars represent the GMT and whiskers the 95% confidence interval. Dashed line indicates the limit 
of detection for the assay. Nonresponders were assigned a value of half the limit of detection, for visualization. Prevaccination and postvaccination immune sera from naive 
(B) and preimmune (D) subjects were also tested for ability to block the binding of monoclonal Ab 5J7 to DENV-3. Within each graph, each individual is assigned the same 
color, to enable visualization of each person’s nAb titers to the different viruses. *P < .05, by the Wilcoxon test, for comparison of the parental backbone DENV to the rDENV.
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Figure 7. Study 203 cartography. A, In Study 203 naive subjects, antigenic mapping shows that putting the 1F4 epitope from dengue virus serotype 1 (DENV-1) into the 
DENV-3 backbone shifts the neutralization away from DENV-3 and DENV-1 (red arrow). Putting the EDIII domain from DENV-2 into DENV-4 moves the neutralization from 
DENV-4 to DENV-2 (blue arrow). Putting the 5J7 epitope from DENV-3 into the DENV-4 backbone moves the response away from the DENV-4 and closer to the DENV-3 
response (green arrow). B, In Study 203 preimmune subjects, antigenic mapping shows that putting the 1F4 epitope from DENV-1 into the DENV-3 backbone shifts the neutral-
ization away from DENV-3 and toward the DENV-1 response (red arrow). Putting the EDIII domain from DENV-2 into DENV-4 moves the neutralization from DENV-4 to DENV-2 
(blue arrow). Putting the 5J7 epitope from DENV-3 into the DENV-4 backbone moves the response away from the DENV-4 and closer to the DENV-3 response (green arrow).
loop domain of the E glycoprotein, which also elicits binding 
Abs that interfere with the specificity of the 2D22 blockade 
assay [33].
We also evaluated subjects with DENV-1 nAbs responses 
after vaccination. Among naive subjects who developed 
DENV-1 nAbs after vaccination, Abs that neutralized rDENV-
3/1 displaying the 1F4 epitope were significantly greater than 
the nAb titer against the parental DENV-3 strain. Consistent 
with these findings, the blockade of binding assay demonstrated 
the presence of Abs in dengue-naive TDV recipients that pre-
vented human mAb 1F4 from binding to DENV-1. Together, 
these results demonstrate that TDV can elicit nAbs directed to 
the complex serotype-specific epitope region defined by mAb 
1F4 in dengue-naive subjects. The use of the rDENV-3/1 proved 
more challenging in the preimmune subjects, owing to the 
high titers of nAbs to both the parental DENV-1 and DENV-3 
strains. However, sera from vaccinated dengue-preimmune 
subjects also blocked 1F4 binding to its epitope on DENV-1, 
indicating that vaccination elicited Abs that bind to or near the 
1F4 epitope. While we recognize that Abs binding close to the 
1F4 epitope may sterically hinder 1F4 binding, the combined 
approaches provide support for the hypothesis that the TDV-1 
vaccine component elicited binding and functionally neutraliz-
ing Abs directed to the 1F4 epitope in some individuals.
The majority of subjects evaluated in this study from both the 
dengue-naive and preimmune groups had Abs that neutralized 
DENV-3. While we were unable to conclusively detect nAbs 
that tracked with the DENV-3 5J7 epitope, these results should 
be interpreted with caution. Many individuals selected for this 
study had high levels of nAbs to both DENV-3 and DENV-4. In 
rDENV-4/3, a gain of DENV-3 nAbs could be masked by a loss of 
an epitope targeted by DENV-4 nAbs [35]. Mapping the DENV-3 
response is also complicated by the genotype differences between 
the TDV and UNC DENV strains. As shown by our group pre-
viously, DENV-3 genotypes have up to 10-fold significant differ-
ences in polyclonal neutralization phenotypes [28]. There are 5 
amino acid differences within the mAb 5J7 epitope, 3 of which are 
contact residues, between the TDV3 and UNC3001strains used 
for the study. A single contact residue change can dramatically 
reduce neutralization, complicating interpretation of DENV-3 
epitope-specific responses. While 5J7 can bind and neutralize the 
both the UNC3001 and TDV3 strains, new recombinant viruses 
may be required to specifically map the 5J7 epitope-specific 
responses in vaccinees receiving TDV. Recently, several DENV-4 
type-specific nAbs have been identified from natural human 
infections and experimental non-human primate studies [35]. 
We are currently developing reagents to map DENV-4 type-spe-
cific nAb responses and anticipate using these reagents to map 
TDV responses in the near future.
Conventionally, antigenic cartography has been widely used 
to compare antigenic relatedness between different strains of 
viruses [32, 36]. Here we modified the approach to determine 
whether the Takeda TDV induced nAbs that tracked with epi-
topes displayed on recombinant DENVs. In the cartography 
map based on nAbs induced by TDV, the DENV-4/2 chimera 
mapped closer to DENV-2 than to DENV-4, suggesting that 
most if not all TDV2 Ab responses target the DENV-2 EDIII dis-
played on DENV-4. Both rDENV-3/1 and rDENV-4/3 demon-
strated shifts toward the donor strain, as well, although the shift 
was not as pronounced as in the case of rDENV-4/2 strain. In 
summary our data demonstrate that, in both naive and preim-
mune individuals who received TDV, the TDV-2 vaccine com-
ponent elicited robust type-specific nAb responses to epitopes 
on EDIII of DENV-2. TDV also induced nAb responses that 
tracked with DENV-1 type-specific 1F4 epitope in some sub-
jects. While our data demonstrate the presence TDV-induced 
Abs that bind at or near the DENV-3 5J7 epitope, we were 
unable to detect functionally nAbs directed to this epitope.
As TDV progresses through its phase 2 and 3 clinical tri-
als, the data and methods reported in this study can be used 
to understand how Abs elicited by vaccination protect people 
from infection and disease. Our study has some limitations that 
need to be addressed before large sample sets from large clinical 
studies can be tested. Many individuals selected for the current 
study had high levels of nAbs to both the transplant and recipi-
ent serotypes. In these individuals, a gain of neutralization due 
to the transplanted epitope could be masked by a loss of a crit-
ical neutralizing site in the recipient strain. This is issue is par-
ticularly relevant to rDENV-3/1 and rDENV-4/3 because the 
known type-specific epitopes on these serotypes are adjacent to 
each other. In future studies, we plan to deplete all Abs to the 
recipient strain so that we can unambiguously track the prop-
erties of the remaining type-specific Abs. Our studies are also 
confounded by sequence differences between TDV strains and 
the recombinant chimeric viruses used for mapping. In partic-
ular, the region defined by the DENV-3 5J7 epitope are variable 
between TDV-3 and the UNC DENV-3 infectious clone. We 
are currently building recombinant viruses that are matched 
to epitopes on TDV viruses. Finally, some of the vaccine sera 
used in this study had detectable DENV-1 or DENV-3 nAbs in 
the Vero cell assay used at Takeda but not in the U937+DC-
SIGN neutralization assay used for epitope mapping. Further 
studies are needed to understand these cell-type–dependent 
differences and how they relate to vaccine performance. In con-
clusion, this study provides a foundation for the development 
of high-throughput assays for use in DENV vaccine trials to 
understand the contribution of Abs to protective immunity.
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